Literature DB >> 9537512

TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling.

G Pan1, J Ni, G Yu, Y F Wei, V M Dixit.   

Abstract

TRAIL/Apo-2L induces rapid apoptosis of a variety of tumor cell lines. A family of tumor necrosis factor receptor-related molecules have been identified as receptors for TRAIL. Herein, we report the identification of another member of the TRAIL receptor family, TRUNDD (TRAIL receptor with a truncated death domain). The TRUNDD transcript was detected in multiple human tissues. TRUNDD is highly homologous to all known TRAIL receptors and has an extracellular TRAIL-binding domain but lacks a functional intracellular death domain and does not induce apoptosis. Consistent with an inhibitory role, ectopic expression of TRUNDD attenuated TRAIL-induced apoptosis in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9537512     DOI: 10.1016/s0014-5793(98)00135-5

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  58 in total

Review 1.  Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.

Authors:  B G Darnay; B B Aggarwal
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Mechanisms of apoptosis.

Authors:  J C Reed
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

Review 3.  TRAIL, Bim, and thymic-negative selection.

Authors:  Shi-Jun Zheng; Youhai H Chen
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

4.  Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.

Authors:  Erik L Brincks; Tamara A Kucaba; Britnie R James; Katherine A Murphy; Kathryn L Schwertfeger; Veena Sangwan; Sulagna Banerjee; Ashok K Saluja; Thomas S Griffith
Journal:  FEBS J       Date:  2015-10-18       Impact factor: 5.542

5.  Augmentation of tumor necrosis factor family-induced apoptosis by E3330 in human hepatocellular carcinoma cell lines via inhibition of NF kappa B.

Authors:  Yukiko Saitou; Katsuya Shiraki; Takenari Yamanaka; Kazumi Miyashita; Tomoko Inoue; Yutaka Yamanaka; Yumi Yamaguchi; Naoyuki Enokimura; Norihiko Yamamoto; Keiichi Itou; Kazushi Sugimoto; Takeshi Nakano
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

6.  The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms.

Authors:  Kirsten Kabsch; Angel Alonso
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

7.  Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma.

Authors:  Kan Kondo; Seiji Yamasaki; Naoya Inoue; Tomoharu Sugie; Naoki Teratani; Takatsugu Kan; Yutaka Shimada
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

Review 8.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

Review 9.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

10.  Antitumor activity of TRAIL recombinant adenovirus in human malignant glioma cells.

Authors:  Ki-Uk Kim; Su-Yeong Seo; Ki-Young Heo; Young-Hyun Yoo; Hye-Jin Kim; Hyeong-Sik Lee; Sun-Seob Choi; Tae-Ho Hwang; Hye-Jeong Lee
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.